Block et al. even found in their placebo controlled trial among 148 patients with moderate CKD (eGFR 20–45 ml/min/1.73 m2), an increase of intact FGF23 with the use of calcium acetate as a phosphate binder [127]. Here, FGF23 is linked to chronic kidney disease.